Jefferies Reiterates Hikma Pharmaceuticals (HKMPF) Buy Recommendation

Jefferies reiterated a Buy recommendation for Hikma Pharmaceuticals (OTCPK:HKMPF) on November 7, 2025, with an average one-year price target of $33.13, implying a 31.21% upside from its $25.25 closing price. This positive outlook contrasts with projected annual revenue declining by 10.45% to $2,880MM and a non-GAAP EPS of $2.12. Despite a slight decrease in the number of institutional holders, total institutional shares in HKMPF surged by 38.93% to 8,508K, and the average portfolio weight dedicated to the stock increased by 24.30%, indicating strong conviction from some institutional investors, notably John Hancock Disciplined Value International Fund.

Analysis

Jefferies reiterated a "Buy" recommendation for Hikma Pharmaceuticals (OTCPK:HKMPF) on November 7, 2025, setting an average one-year price target of $33.13/share. This target implies a significant 31.21% upside from the latest reported closing price of $25.25/share, indicating a strong analyst conviction despite a projected 10.45% decrease in annual revenue to $2,880MM and a non-GAAP EPS of $2.12.

Despite a marginal decrease of 2.44% in the number of institutional owners, total shares held by institutions in HKMPF increased substantially by 38.93% to 8,508K shares over the last three months. Concurrently, the average portfolio weight dedicated to HKMPF across all funds rose by 24.30%, signaling increased conviction among existing institutional holders.

This aggregate increase is largely driven by significant accumulation from funds like John Hancock Disciplined Value International Fund (JDIBX), which boosted its holdings by 62.34% to 2,430K shares and increased its portfolio allocation by 83.23%. Conversely, other major institutional investors such as Vanguard Total International Stock Index Fund (VGTSX) and Vanguard Developed Markets Index Fund (VTMGX) reduced their positions by 4.37% and 3.48% respectively, alongside decreasing their portfolio allocations.

Key Decisions for Investors

• Investors should carefully evaluate the rationale behind Jefferies' "Buy" recommendation and 31.21% price target upside, especially considering the projected 10.45% annual revenue decrease.
• Monitor the evolving institutional ownership landscape, noting the overall increase in shares held by institutions alongside the mixed signals from individual fund adjustments.
• Consider the strong conviction demonstrated by specific funds like John Hancock Disciplined Value International Fund, which significantly increased its allocation, as a potential indicator of underlying value.